Obstetric anti-phospholipid syndrome: from pathogenesis to treatment
Antiphospholipid syndrome (APS) is an autoimmune disease characterized by clinical manifestations such as thrombosis and obstetric complications with documented persistence of antiphospholipid antibodies (aPLs). Recent studies have revealed that the cause of aPL-related obstetric complications is dy...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2021-08-01
|
| Series: | Immunological Medicine |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/25785826.2021.1969116 |
| _version_ | 1818692193809858560 |
|---|---|
| author | Kayoko Kaneko Nobuaki Ozawa Atsuko Murashima |
| author_facet | Kayoko Kaneko Nobuaki Ozawa Atsuko Murashima |
| author_sort | Kayoko Kaneko |
| collection | DOAJ |
| description | Antiphospholipid syndrome (APS) is an autoimmune disease characterized by clinical manifestations such as thrombosis and obstetric complications with documented persistence of antiphospholipid antibodies (aPLs). Recent studies have revealed that the cause of aPL-related obstetric complications is dysfunction of placental trophoblasts and inflammation of the maternal–fetal interface induced by aPLs, not thrombosis. Although aPLs are associated with recurrence of serious complications during pregnancy, appropriate combination therapy with heparin and low-dose aspirin can improve the course of 70–80% of subsequent pregnancies. Preconception counseling and patient-tailored treatment are fundamental to improving maternal and fetal outcomes. Non-anticoagulant treatments such as hydroxychloroquine and statins are being developed for cases refractory to conventional treatment. Risk factors for thrombosis after pregnancy complications were identified based on the analysis of large databases of obstetric APS. |
| first_indexed | 2024-12-17T12:53:54Z |
| format | Article |
| id | doaj.art-fc028cb73fb1453cb4bb2dc8e8e86fcc |
| institution | Directory Open Access Journal |
| issn | 2578-5826 |
| language | English |
| last_indexed | 2024-12-17T12:53:54Z |
| publishDate | 2021-08-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Immunological Medicine |
| spelling | doaj.art-fc028cb73fb1453cb4bb2dc8e8e86fcc2022-12-21T21:47:31ZengTaylor & Francis GroupImmunological Medicine2578-58262021-08-010011510.1080/25785826.2021.19691161969116Obstetric anti-phospholipid syndrome: from pathogenesis to treatmentKayoko Kaneko0Nobuaki Ozawa1Atsuko Murashima2Division of Maternal Medicine, Center for Maternal-Fetal, Neonatal and Reproductive Medicine, National Center for Child Health and DevelopmentDivision of Reproductive Medicine and Maternal Care/Immunology, Center for Maternal-Fetal, Neonatal and Reproductive Medicine, National Center for Child Health and DevelopmentDivision of Maternal Medicine, Center for Maternal-Fetal, Neonatal and Reproductive Medicine, National Center for Child Health and DevelopmentAntiphospholipid syndrome (APS) is an autoimmune disease characterized by clinical manifestations such as thrombosis and obstetric complications with documented persistence of antiphospholipid antibodies (aPLs). Recent studies have revealed that the cause of aPL-related obstetric complications is dysfunction of placental trophoblasts and inflammation of the maternal–fetal interface induced by aPLs, not thrombosis. Although aPLs are associated with recurrence of serious complications during pregnancy, appropriate combination therapy with heparin and low-dose aspirin can improve the course of 70–80% of subsequent pregnancies. Preconception counseling and patient-tailored treatment are fundamental to improving maternal and fetal outcomes. Non-anticoagulant treatments such as hydroxychloroquine and statins are being developed for cases refractory to conventional treatment. Risk factors for thrombosis after pregnancy complications were identified based on the analysis of large databases of obstetric APS.http://dx.doi.org/10.1080/25785826.2021.1969116obstetric antiphospholipid syndrometrophoblastspregnancyfetal lossrecurrent early miscarriage |
| spellingShingle | Kayoko Kaneko Nobuaki Ozawa Atsuko Murashima Obstetric anti-phospholipid syndrome: from pathogenesis to treatment Immunological Medicine obstetric antiphospholipid syndrome trophoblasts pregnancy fetal loss recurrent early miscarriage |
| title | Obstetric anti-phospholipid syndrome: from pathogenesis to treatment |
| title_full | Obstetric anti-phospholipid syndrome: from pathogenesis to treatment |
| title_fullStr | Obstetric anti-phospholipid syndrome: from pathogenesis to treatment |
| title_full_unstemmed | Obstetric anti-phospholipid syndrome: from pathogenesis to treatment |
| title_short | Obstetric anti-phospholipid syndrome: from pathogenesis to treatment |
| title_sort | obstetric anti phospholipid syndrome from pathogenesis to treatment |
| topic | obstetric antiphospholipid syndrome trophoblasts pregnancy fetal loss recurrent early miscarriage |
| url | http://dx.doi.org/10.1080/25785826.2021.1969116 |
| work_keys_str_mv | AT kayokokaneko obstetricantiphospholipidsyndromefrompathogenesistotreatment AT nobuakiozawa obstetricantiphospholipidsyndromefrompathogenesistotreatment AT atsukomurashima obstetricantiphospholipidsyndromefrompathogenesistotreatment |